Suchergebnisse - (Person:"Curtin, Nicola")

PubPharm (15)

1

Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers

enthalten in: Cancer discovery | 2017

von de Bono, J. | Ramanathan, R. | Mina, L. | +13

2

Strategies Employed for the Development of PARP Inhibitors

enthalten in: Methods in molecular biology (Clifton, N.J.) | 2017

von Canan, S. | Maegley, K. | Curtin, N.

3

Poly(ADP-Ribose) Polymerase in Cervical Cancer Pathogenesis : Mechanism and Potential Role for PARP Inhibitors

enthalten in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | 2016

von Kotsopoulos, I. | Kucukmetin, A. | Mukhopadhyay, A. | +2

4

PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia

enthalten in: Oncotarget | 2015

von Herriott, A. | Tudhope, S. | Junge, G. | +13

5

PARP activity in peripheral blood lymphocytes as a predictive biomarker for PARP inhibition in tumor tissues - A population pharmacokinetic/pharmacodynamic analysis of rucaparib

enthalten in: Clinical pharmacology in drug development | 2015

von Wang, D. | Li, C. | Sun, W. | +7

6

Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itself

enthalten in: PloS one | 2015

von McCrudden, C. | O'Rourke, M. | Cherry, K. | +14

7

Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma

enthalten in: Current opinion in oncology | 2014

von Vormoor, B. | Curtin, N.

8

PARP inhibitors for anticancer therapy

enthalten in: Biochemical Society transactions | 2014

von Curtin, N.

9

Therapeutic applications of PARP inhibitors : anticancer therapy and beyond

enthalten in: Molecular aspects of medicine | 2013

von Curtin, N. | Szabo, C.

10

Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies

enthalten in: Haematologica | 2013

von Gaymes, T. | Mohamedali, A. | Patterson, M. | +8